Citi analyst Peter Verdult resumed coverage of Eli Lilly (LLY) with a Buy rating and $1,060 price target after a period of rating suspended. The firm cites increased tirzepatide forecasts based on latest reported sales, script trends, and raised expectations for pipeline asset orforglipron for the Buy rating. Citi also sees a diminished competitive threat from Roche’s (RHHBY) oral GLP-1 CT-996 due to elevated heart rate and high nausea instance. It prefers Eli Lilly and Merck (MRK) among the U.S. pharma majors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Roche obesity pill tied to high rates of nausea in ST study, Bloomberg says
- Eli Lilly announces $1B expansion of Ireland manufacturing site
- Novo Nordisk rises as early weight-loss pill data impresses Street
- Eli Lilly says QWINT-2 trial met primary endpoint of non-inferior A1C reduction
- Eli Lilly: QWING-2 ph3 trial met primary endpoint of non-inferior A1C reduction